Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

checkorphan
Learn more about:
Acute mountain sickness
Related Clinical Trial
Colorado-Oregon Altitude Study The Effects of Intermittent Hypoxia on Acute Hypoxic Injury Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude The Pre-acclimatization Augmented Extreme Altitude Expedition Effect of Altitude on Iron Absorption in Iron Depleted Women Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD HIGH Altitude CArdiovascular REsearch Latin America Population Study Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

Official Title

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

Brief Summary

      This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention
      of acute mountain sickness. These drugs have never been directly compared for efficacy. The
      study population is hikers who are ascending at their own rate under their own power in a
      true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and
      Bancroft Station (BAR), Bancroft Peak, White Mountain, California.

Detailed Description

      The specific aim of this study is to evaluate if acetazolamide will be similar to ibuprofen
      (i.e. Ibuprofen being non-inferior) in decreasing the incidence of Acute Mountain Sickness
      (AMS) in travelers to high altitude. It has been shown that ibuprofen taken 3 times a day 6
      hours prior to ascent is effective for the prevention of AMS, with a number needed to treat
      of 4, decreasing the odds of getting AMS by a third. The efficacy appears to be similar to
      acetazolamide, with a NNT of 3 -8, although these two medications have not been directly
      compared in prevention of AMS. Acetazolamide is diuretic that is the only FDA approved AMS
      prophylactic medication and the most commonly used drug for AMS prevention. Although
      acetazolamide has been given a 1A indication, it has been shown to limit exercise
      capabilities at high altitude, and rapid ascent has been shown to attenuate its protective
      effects. Ibuprofen has been given a IIB recommendation by the Wilderness Medical Society
      Practice Guidelines, in part because it has not directly compared to acetazolamide. It is
      unknown if a non-steroidal anti-inflammatory can provide protection from AMS equivalent to
      acetazolamide.

Study Phase

Phase 1

Study Type

Interventional

Primary Outcome

incidence of acute mountain sickness

Secondary Outcome

 severity of acute mountain sickness

Condition

Acute Mountain Sickness

Intervention

Ibuprofen

Study Arms / Comparison Groups

 Ibuprofen
Description:  ibuprofen, 600mg, three times a day, through to ascent to high altitude

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

92

Start Date

August 12, 2017

Completion Date

October 1, 2017

Primary Completion Date

October 1, 2017

Eligibility Criteria

        Inclusion Criteria:

          1. Age 18-65 healthy non-pregnant volunteer

          2. Sea-level dwelling (live at low elevation < 4000 ft)

          3. Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend

          4. Available for full study duration (Friday PM-Sunday AM)

        Exclusion Criteria:

          1. Age <18 or >65, Pregnant, Live at altitude >4000 ft

          2. Slept at altitude > 4000ft within 1 week of study

          3. Allergic to acetazolamide, sulfa drugs, or non-steroidal anti-inflammatories

          4. Taking NSAIDs, Acetazolamide, or Corticosteroids 1 week prior to study

          5. Medical History of Brain Tumor, increased brain pressure, pseudotumor cerebri, VP
             shunts, HACE, or HAPE.

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT03154645

Organization ID

40325

Responsible Party

Sponsor-Investigator

Study Sponsor

Grant S Lipman

Study Sponsor

, ,

Verification Date

November 2018